Articles published by Daiichi Sankyo

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

October 02, 2026

From Daiichi Sankyo

Via Business Wire

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

September 25, 2026

From Daiichi Sankyo

Via Business Wire

Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

September 13, 2026

From Daiichi Sankyo

Via Business Wire

DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo

August 27, 2026

From Daiichi Sankyo

Via Business Wire

TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer

August 26, 2026

From Daiichi Sankyo

Via Business Wire

Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio

August 24, 2026

From Daiichi Sankyo

Via Business Wire

Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

August 17, 2026

From Daiichi Sankyo

Via Business Wire

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

July 31, 2026

From Daiichi Sankyo

Via Business Wire

Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO

May 28, 2026

From Daiichi Sankyo

Via Business Wire

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

May 22, 2026

From Daiichi Sankyo

Via Business Wire

Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer

May 15, 2026

From Daiichi Sankyo

Via Business Wire

Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation

May 11, 2026

From Daiichi Sankyo

Via Business Wire

Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

April 13, 2026

From Daiichi Sankyo

Via Business Wire

Tickers MRK

ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

March 09, 2026

From Daiichi Sankyo

Via Business Wire

Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D

February 19, 2026

From Daiichi Sankyo

Via Business Wire

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

February 04, 2026

From Daiichi Sankyo

Via Business Wire

DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

February 03, 2026

From Daiichi Sankyo

Via Business Wire

Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe

January 22, 2026

From Daiichi Sankyo

Via Business Wire

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

January 13, 2026

From Daiichi Sankyo

Via Business Wire

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer

December 22, 2025

From Daiichi Sankyo

Via Business Wire

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer

December 22, 2025

From Daiichi Sankyo

Via Business Wire

ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

December 15, 2025

From Daiichi Sankyo

Via Business Wire

DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer

December 09, 2025

From Daiichi Sankyo

Via Business Wire

Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS

December 08, 2025

From Daiichi Sankyo

Via Business Wire

Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen

December 03, 2025

From Daiichi Sankyo

Via Business Wire

DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo

November 10, 2025

From Daiichi Sankyo

Via Business Wire

DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer

October 30, 2025

From Daiichi Sankyo

Via Business Wire

DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial

October 19, 2025

From Daiichi Sankyo

Via Business Wire

Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial

October 19, 2025

From Daiichi Sankyo

Via Business Wire

Tickers MRK

DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02

October 19, 2025

From Daiichi Sankyo

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.